Efficacy and effects of Ruxolitinib tablets (Ruxolitinib)

In two major studies involving528 patients, Ruxolitinib was more effective than placebo and was the best treatment for reducing the size of the spleen. In the first study, 42% of patients who received ruxolitinib achieved a 35% reduction in spleen size after 6 months. In the second study, 29% of patients who received ruxolitinib achieved a goal of reducing spleen size by 35% after one year, while none of the 72 patients who received optimal treatments, such as cancer drugs, hormones and immunosuppressants, achieved the goal.

Ruxolitinib tablets improved patient outcomes in a major study involving 222 patients for whom hydroxybutylamine didn't work or caused unacceptable side effects. The improvement was measured as requiring less than one phlebotomy treatment (removing excess blood from the body) and a reduction in spleen size of at least 35%. In this study, 21% of patients treated with ruxolitinib tablets showed improvement after eight months, compared with only 1% of patients who received optimal treatment.

In two major studies, ruxolitinib tablets were effective in reducing symptoms of acute and chronic graft-versus-host disease. The study involved 309 patients who developed acute graft-versus-host disease after receiving an allogeneic stem cell transplant (using stem cells from a donor) and who did not respond to corticosteroid treatment. The study looked at the proportion of patients who experienced a reduction in symptoms (partial response) or no signs of symptoms (complete response) after four weeks of treatment with ruxolitinib tablets or the best treatment for their disease. In this study, 62% of patients who received treatment had a complete or partial response to treatment.